1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: On February 26, 2024 , Julie McHugh , a member of our Board , entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”), providing for the potential sale of up to 2,500 shares of our common stock on May 28, 2024.
−Removed: On February 27, 2024 , Heinz Mäusli , a member of our Board , entered into a 10b5-1 Plan providing for the potential sale of up to 25,692 shares of our common stock, including shares obtained from the exercise of vested stock options covered by the 10b5-1 Plan, between May 28, 2024 and September 30, 2024.
−Removed: On March 1, 2024 , Paul Blanchfield , our President , entered into a 10b5-1 Plan providing for the potential sale of up to 7,263 shares of our common stock, between May 31, 2024 and March 5, 2025.
−Removed: Pursuant to the 10b5-1 Plan, Mr.
−Removed: Blanchfield will also make a gift of 355 shares of common stock on November 14, 2024.
−Removed: On March 1, 2024 , Daniel Niedzwiecki , our Chief Administrative Officer, General Counsel and Corporate Secretary , entered into a 10b5-1 Plan providing for the potential sale of up to 15,373 shares of our common stock, between May 30, 2024 and August 30, 2024.
−Removed: On March 13, 2024 , Mary Anne Heino , a member of our Board , entered into a 10b5-1 Plan.
−Removed: The plan provides for the sale of shares of our common stock between August 2, 2024 and March 31, 2025 in an amount (i) sufficient to cover tax withholding obligations in connection with the potential vesting and settlement of up to 117,006 outstanding RSUs and PSUs plus (ii) an additional number of shares necessary to result in approximate net sale proceeds of $2,000,000 in the aggregate.
+Added: On May 7, 2024 , Gérard Ber , a member of our Board , entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”), providing for the potential sale of up to 15,500 shares of our common stock between September 11, 2024 and April 11, 2025 .
+Added: On May 21, 2024 , James Thrall , a member of our Board , entered into a 10b5-1 Plan providing for the potential sale of up to 2,000 shares of our common stock between August 21, 2024 and January 15, 2025 .
INCORPORATED BY REFERENCE
1 unchanged sentence
NUMBER EXHIBIT FILING
−Removed: 10.1* First Amendment to License and Collaboration Agreement (PNT-2002), dated as of January 31, 2024, by and between POINT Biopharma, Inc.
−Removed: and Lantheus Two, LLC and Lantheus Medical Imaging, Inc.
+Added: 10.1 Seventh Amendment to Lantheus Holdings, Inc.
+Added: 2015 Equity Incentive Plan
+Added: 8-K 001-36569 10.1 April 29, 2024
+Added: 10.2*+†† Consulting Agreement by and between Lantheus Medical Imaging, Inc.
+Added: and Etienne Montagut, effective as of June 7, 2024
31.1* Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a).
11 unchanged sentences
** Furnished herewith.
+Added: + Indicates management contract or compensatory plan or arrangement.
+Added: †† Portions of this exhibit have been omitted for confidential treatment pursuant to Item 601(b)(10)(iv) of Regulation S-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
4 unchanged sentences
(Principal Executive Officer)
+Added: July 31, 2024
LANTHEUS HOLDINGS, INC.
4 unchanged sentences
(Principal Financial Officer)
+Added: July 31, 2024
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.